C. Zielinski

2.8k total citations · 1 hit paper
51 papers, 2.0k citations indexed

About

C. Zielinski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Zielinski has authored 51 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in C. Zielinski's work include Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (7 papers). C. Zielinski is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (7 papers). C. Zielinski collaborates with scholars based in Austria, Switzerland and United States. C. Zielinski's co-authors include David Cameron, Damien C. Weber, Gary H. Lyman, Nora Kearney, Matti Aapro, Julia Bohlius, Ruth Pettengell, Jan Walewski, Vivianne C. G. Tjan‐Heijnen and Michael Hejna and has published in prestigious journals such as Journal of Clinical Oncology, European Heart Journal and British Journal of Cancer.

In The Last Decade

C. Zielinski

48 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

2010 777 citations Matti Aapro, Julia Bohlius et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by C. Zielinski

Since Specialization

Citations

This map shows the geographic impact of C. Zielinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Zielinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Zielinski more than expected).

Fields of papers citing papers by C. Zielinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Zielinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Zielinski. The network helps show where C. Zielinski may publish in the future.

Co-authorship network of co-authors of C. Zielinski

This figure shows the co-authorship network connecting the top 25 collaborators of C. Zielinski. A scholar is included among the top collaborators of C. Zielinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Zielinski. C. Zielinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bioaccessibility and anti-inflammatory activity in Caco-2 cells of phytochemicals from industrial by-products of coffee (Coffea arabica L.) 2025 ·Journal of Functional Foods ·(unknown), C. Zielinski, Patricia Esquivel, Jan Frank, (unknown), Felipe Jiménez‐Aspee	0
2	A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) 2012 ·Haematologica ·Barbara Kiesewetter, Marlene Troch, Werner Dolak, Leonhard Müllauer, Julius Lukas, C. Zielinski, Markus Raderer	65
3	Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer 2012 ·European Journal of Cancer ·(unknown), Moshe Inbar, Zsuzsanna Kahán, Richard Greil, S. Beslija, Salomon M. Stemmer, Bella Kaufman, Zanete Zvirbule, Guenther G. Steger, Diethelm Messinger, Thomas Brodowicz, C. Zielinski	16
4	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours breakdown → 2010 ·European Journal of Cancer ·Matti Aapro, Julia Bohlius, David Cameron, Lissandra Dal Lago, J. Peter Donnelly, Nora Kearney, Gary H. Lyman, Ruth Pettengell, Vivianne C. G. Tjan‐Heijnen, Jan Walewski, Damien C. Weber, C. Zielinski	777
5	Health-related quality of life (HQOL) and early survival outcome of the randomized adjuvant dose-dense (dd) FEC₇₅ versus FEC₉₀ CECOG study. 2010 ·Journal of Clinical Oncology ·Zsuzsanna Kahán, S. Špánik, M Wagnerová, Jacek Jassem, Tomáš Skácel, Katarzyna Elandt, (unknown), (unknown), C. Zielinski, Thomas Brodowicz	1
6	Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells 2008 ·Journal of Clinical Oncology ·Friedegund Meier, C. Zielinski, Konstantinos Lasithiotakis, Tobias Sinnberg, Keith T. Flaherty, Birgit Schittek, Dagmar Kulms, Claus Garbe	2
7	Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) 2008 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, C. Zielinski, (unknown), (unknown), Maike Schmidt, Holger Eidtmann, Tanja Čufer, Felix E. de Jongh, M. Kaufmann, Sibylle Loibl	52
8	Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. 2006 ·PubMed ·Swen Langer, C Singer, Gernot Hudelist, Brigitta Dampier, Klaus Kaserer, Ursula Vinatzer, Hubert Pehamberger, C. Zielinski, E. Kubista, (unknown)	50
9	Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable 2006 ·British Journal of Cancer ·Ursula Vogl, Harald Zehetgruber, Martin Dominkus, Michael Hejna, C. Zielinski, Andrea Haitel, Manuela Schmidinger	85
10	EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours 2006 ·European Journal of Cancer ·Matti Aapro, David Cameron, Ruth Pettengell, Julia Bohlius, Jeffrey Crawford, Michael Ellis, Nora Kearney, Gary H. Lyman, Vivianne C. G. Tjan‐Heijnen, Jan Walewski, Damien C. Weber, C. Zielinski	368
11	Oral vinorelbine in the treatment of advanced breast cancer 2004 ·Journal of Clinical Oncology ·Rupert Bartsch, Ursula Pluschnig, C. Wenzel, (unknown), Gottfried J. Locker, Robert M. Mader, C. Zielinski, G. Steger	7
12	A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer 2003 ·Annals of Oncology ·Robert Paridaens, F. Van Aelst, Vassilis Georgoulias, (unknown), V. Cocquyt, C. Zielinski, H. Hausmaninger, (unknown), (unknown), J. Wildiers, (unknown), N. Azli	18
13	Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines 2003 ·European Journal of Cancer ·(unknown), W. Koestler, Peter Horak, Thomas W. Grunt, T. Brodowicz, Ingrid Pribill, (unknown), (unknown), (unknown), C. Zielinski, Michael Krainer	32
14	Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features 2003 ·Annals of Oncology ·H. Kaufmann, J Ackermann, Hildegard Greinix, Thomas Nösslinger, Heinz Gisslinger, Andrea Keck, Heinz Ludwig, Nina Worel, Peter Kalhs, C. Zielinski, Johannes Drach	2
15	Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status 2001 ·British Journal of Cancer ·Thomas Brodowicz, Daniela Kandioler, (unknown), Christian Ludwig, Margaretha Rudas, Rainer Kunstfeld, W. Koestler, Michael Hejna, Alexandra C. Budinsky, C Wiltschke, C. Zielinski	19
16	Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment 2001 ·CA A Cancer Journal for Clinicians ·Wolfgang J. Köstler, Michael Hejna, C. Wenzel, C. Zielinski	266
17	Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids 1999 ·British Journal of Cancer ·Thomas Brodowicz, C Wiltschke, Daniela Kandioler-Eckersberger, Thomas W. Grunt, Margaretha Rudas, Sebastian Schneider, Michael Hejna, Alexandra C. Budinsky, C. Zielinski	29
18	Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor 1998 ·European Journal of Cancer ·Herbert Stöger, H. Samonigg, Michael Krainer, (unknown), (unknown), (unknown), (unknown), (unknown), J. Schüller, N. Vavra, Werner Scheithauer, Gabriela Kornek, M. Stierer, C. Zielinski	12
19	Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer 1997 ·Annals of Oncology ·G Brufman, E Colajori, N. Ghilezan, M. Lassus, Monica Martoni, Н И Переводчикова, C. Tosello, (unknown), C. Zielinski	64
20	Der Einfluß verschiedener Faktoren auf das Überleben des rezidivierenden und/oder metastasierenden Mammakarzinoms 1991 ·Geburtshilfe und Frauenheilkunde ·P. Sevelda, I. Kührer, C. Zielinski, N. Vavra, (unknown), E. Kubista, K. Czerwenka, J. Spona, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact